Azitra is trading at $0.72, down -11.51%, amid broad market and biotech weakness.

  • The Nasdaq is down 5.10% and the S&P 500 is down 3.42%.
  • Biotech ETF XBI is down 5.19%, pointing to broader market and sector weakness rather than a clear Azitra-specific catalyst.
  • Recent coverage concerns earlier ATR-COSF study results and a planned presentation; no fresh company-specific catalyst was identified for November 5.